Covered recipient · General Payments record
ASHKAN ABBEY
Allopathic & Osteopathic Physicians Ophthalmology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$86,653.29
133 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $39,911.02 | 19 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $36,854.30 | 13 |
| Food and Beverage | $4,658.67 | 90 |
| Travel and Lodging | $3,839.30 | 10 |
| Honoraria | $1,390.00 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Apellis Pharmaceuticals, Inc. | $25,346.74 | 25 |
| Astellas Pharma US Inc | $13,927.60 | 12 |
| EyePoint Pharmaceuticals US, Inc. | $11,288.30 | 13 |
| Regeneron Healthcare Solutions, Inc. | $8,745.60 | 24 |
| Hoffmann-La Roche Limited | $7,082.65 | 2 |
| Genentech USA, Inc. | $4,466.21 | 5 |
| Regeneron Pharmaceuticals, Inc. | $4,284.47 | 3 |
| Bausch & Lomb Americas Inc. | $3,449.14 | 8 |
| ABBVIE INC. | $2,708.12 | 10 |
| Alimera Sciences, Inc. | $2,421.60 | 8 |
| Ocular Therapeutix, Inc. | $2,000.00 | 1 |
| Beaver-Visitec International, Inc. | $350.00 | 1 |
| Sandoz Inc. | $274.51 | 10 |
| Harrow Eye, LLC | $138.51 | 5 |
| Amgen Inc. | $79.54 | 3 |
| Coherus Biosciences Inc. | $66.15 | 2 |
| Biogen, Inc. | $24.15 | 1 |
Page 3 of 3; records 101–133 of 133 matching records. This page contains 33 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ASHKAN ABBEY
NPI 1548402886 · CMS profile ID 161327
Allopathic & Osteopathic Physicians / Ophthalmology
DALLAS, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–133 of 133 matching records. This page contains 33 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1548402886?year=2024&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ASHKAN ABBEY, NPI 1548402886, CMS profile ID 161327. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–133 of 133 matching records. This page contains 33 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1548402886?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). ASHKAN ABBEY, NPI 1548402886, CMS profile ID 161327. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–133 of 133 matching records. This page contains 33 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1548402886?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- ASHKAN ABBEY, NPI 1548402886, CMS profile ID 161327, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–133 of 133 matching records. This page contains 33 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1548402886?year=2024&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
133 matching records · $86,653.29 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–133 of 133.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Alimera Sciences, Inc. | $122.41 | 03/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1092833854 | CMS |
| Apellis Pharmaceuticals, Inc. | $7,095.00 | 03/25/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1154017249 | CMS |
| Apellis Pharmaceuticals, Inc. | $1,301.33 | 03/25/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1154017251 | CMS |
| Apellis Pharmaceuticals, Inc. | $72.21 | 03/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1154017255 | CMS |
| EyePoint Pharmaceuticals US, Inc. | $1,850.00 | 03/22/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089507276 | CMS |
| Astellas Pharma US Inc | $550.00 | 03/21/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139450388 | CMS |
| ABBVIE INC. | $28.19 | 03/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103162682 | CMS |
| Astellas Pharma US Inc | $550.00 | 03/18/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139450428 | CMS |
| Sandoz Inc. | $27.85 | 03/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089367154 | CMS |
| Amgen Inc. | $17.55 | 03/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1111507421 | CMS |
| Alimera Sciences, Inc. | $1,390.00 | 02/27/2024 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1092836503 | CMS |
| Regeneron Healthcare Solutions, Inc. | $121.84 | 02/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1113992949 | CMS |
| Regeneron Healthcare Solutions, Inc. | $60.92 | 02/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1113992951 | CMS |
| Biogen, Inc. | $24.15 | 02/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104825588 | CMS |
| EyePoint Pharmaceuticals US, Inc. | $219.44 | 02/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089508092 | CMS |
| Regeneron Healthcare Solutions, Inc. | $940.00 | 02/23/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1113992945 | CMS |
| Regeneron Healthcare Solutions, Inc. | $2,820.00 | 02/23/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1113992947 | CMS |
| ABBVIE INC. | $28.19 | 02/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103162680 | CMS |
| Hoffmann-La Roche Limited | $5,880.00 | 02/15/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132979437 | CMS |
| Alimera Sciences, Inc. | $184.14 | 02/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1092827700 | CMS |
| Bausch & Lomb Americas Inc. | $23.17 | 02/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1140306096 | CMS |
| Regeneron Healthcare Solutions, Inc. | $33.58 | 02/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1113992943 | CMS |
| Coherus Biosciences Inc. | $33.02 | 02/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147278104 | CMS |
| Regeneron Healthcare Solutions, Inc. | $529.00 | 01/30/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1113992941 | CMS |
| ABBVIE INC. | $28.19 | 01/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103162678 | CMS |
| Apellis Pharmaceuticals, Inc. | $1,500.00 | 01/23/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1154017245 | CMS |
| Apellis Pharmaceuticals, Inc. | $32.18 | 01/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1154017231 | CMS |
| Alimera Sciences, Inc. | $161.98 | 01/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1092831627 | CMS |
| Coherus Biosciences Inc. | $33.13 | 01/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147278094 | CMS |
| Regeneron Healthcare Solutions, Inc. | $28.00 | 01/05/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1113992933 | CMS |
| Regeneron Healthcare Solutions, Inc. | $42.93 | 01/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1113992935 | CMS |
| Regeneron Healthcare Solutions, Inc. | $234.03 | 01/05/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1113992937 | CMS |
| Regeneron Healthcare Solutions, Inc. | $46.24 | 01/05/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1113992939 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $14,735.65 | 3 |
| PY2025 | Principal investigator | $1,051,062.70 | 141 |
| PY2024 | Recipient | $77,990.23 | 16 |
| PY2024 | Principal investigator | $558,687.89 | 68 |
| PY2023 | Principal investigator | $663,687.98 | 38 |
| PY2022 | Principal investigator | $831,052.16 | 52 |
| PY2021 | Principal investigator | $794,526.53 | 39 |
| PY2020 | Principal investigator | $636,290.71 | 28 |
| PY2019 | Principal investigator | $622,417.60 | 14 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
144 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $40.00 | 12/31/2025 | Non-covered Recipient Entity Texas Retina Associates Dallas-Main | A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema | No dispute reported | 06/30/2026 | 1220776251 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,700.00 | 12/15/2025 | Non-covered Recipient Entity Texas Retina Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250240093 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $24,620.40 | 12/12/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250240137 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $28,740.40 | 12/12/2025 | Non-covered Recipient Entity Texas Retina Associates | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226088191 |
| Principal investigator 1 | Genentech, Inc. | $2,734.00 | 12/11/2025 | Non-covered Recipient Entity Texas Retina Associates | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | No dispute reported | 06/30/2026 | 1211663657 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,289.54 | 12/11/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273619 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,330.44 | 12/11/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273621 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,330.44 | 12/11/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184273623 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $32,909.00 | 12/03/2025 | Non-covered Recipient Entity Texas Retina Associates | An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD | No dispute reported | 06/30/2026 | 1250364221 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,649.40 | 12/01/2025 | Non-covered Recipient Entity Southeast Retina Center, Pc | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226107679 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,029.93 | 11/27/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184265969 |
| Principal investigator 1 | Genentech, Inc. | $5,500.00 | 11/21/2025 | Non-covered Recipient Entity Texas Retina Associates | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211663661 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $905.38 | 11/19/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184262577 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $42,249.00 | 11/12/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1B: Randomized PD Pilot; Part 2: Masked, Randomized, Active-comparator-controlled | No dispute reported | 06/30/2026 | 1211663695 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $1,684.00 | 11/07/2025 | Non-covered Recipient Entity Texas Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250364199 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $1,684.00 | 11/07/2025 | Non-covered Recipient Entity Texas Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250364201 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $1,684.00 | 11/07/2025 | Non-covered Recipient Entity Texas Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250364203 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $1,684.00 | 11/07/2025 | Non-covered Recipient Entity Texas Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250364205 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $1,684.00 | 11/07/2025 | Non-covered Recipient Entity Texas Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250364207 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $1,495.00 | 11/07/2025 | Non-covered Recipient Entity Texas Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250364209 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $1,495.00 | 11/07/2025 | Non-covered Recipient Entity Texas Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250364211 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $1,495.00 | 11/07/2025 | Non-covered Recipient Entity Texas Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250364213 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $1,495.00 | 11/07/2025 | Non-covered Recipient Entity Texas Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250364215 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $1,495.00 | 11/07/2025 | Non-covered Recipient Entity Texas Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250364217 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $1,495.00 | 11/07/2025 | Non-covered Recipient Entity Texas Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250364219 |
| Principal investigator 1 | Genentech, Inc. | $26,640.00 | 11/05/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A Phase 1 SAD MD in Diabetic Macular Edema | No dispute reported | 06/30/2026 | 1211663684 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,207.60 | 11/03/2025 | Non-covered Recipient Entity Austin Clinical Research, Llc | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226100230 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $40.00 | 10/31/2025 | Non-covered Recipient Entity Texas Retina Associates Dallas-Main | A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema | No dispute reported | 06/30/2026 | 1220776247 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,330.44 | 10/29/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184255221 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,330.44 | 10/29/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184255223 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $40.00 | 10/28/2025 | Non-covered Recipient Entity Texas Retina Associates Dallas-Main | A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema | No dispute reported | 06/30/2026 | 1220776249 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,497.49 | 10/17/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184251389 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $61,928.10 | 10/17/2025 | Non-covered Recipient Entity Texas Retina Associates | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226101719 |
| Principal investigator 1 | ABBVIE INC. | $260,700.00 | 10/16/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | IIT-2018-10566//The Use of a Combination of Ozurdex and Eylea versus Eylea Monotherapy for Diabetic Macular Edema: A Prospective, Comparative Trial (COED Trial) | No dispute reported | 06/30/2026 | 1202517175 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,520.00 | 10/15/2025 | Non-covered Recipient Entity Texas Retina Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250240091 |
| Principal investigator 1 | ABBVIE INC. | $5,041.54 | 10/14/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy | No dispute reported | 06/30/2026 | 1202516751 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $200.00 | 10/13/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250240143 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,330.44 | 10/03/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184246568 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,922.72 | 10/03/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184246570 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,330.44 | 10/03/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184246572 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,922.72 | 10/03/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184246574 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,922.72 | 10/03/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184246576 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,922.72 | 10/03/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184246578 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,330.44 | 10/03/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184246580 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,330.44 | 10/03/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184246582 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,922.72 | 10/03/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184246584 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,330.44 | 10/03/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184246586 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $40.00 | 09/30/2025 | Non-covered Recipient Entity Texas Retina Associates Dallas-Main | A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema | No dispute reported | 06/30/2026 | 1220776245 |
| Principal investigator 1 | Genentech, Inc. | $29,801.00 | 09/26/2025 | Non-covered Recipient Entity Texas Retina Associates | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | No dispute reported | 06/30/2026 | 1211663642 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,305.03 | 09/24/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184242413 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,305.03 | 09/24/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184242415 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,305.03 | 09/24/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184242417 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,922.72 | 09/24/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184242419 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,185.46 | 09/11/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184236041 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,184.84 | 09/11/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184236043 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,132.06 | 09/11/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184236045 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,293.00 | 09/10/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184235697 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,062.00 | 09/10/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184235699 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $14,416.35 | 09/05/2025 | Non-covered Recipient Entity Texas Retina Associates | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226088180 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $57.91 | 09/03/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250240121 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $43,874.10 | 09/03/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250240123 |
| Principal investigator 1 | ABBVIE INC. | $16,341.42 | 09/02/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) | No dispute reported | 06/30/2026 | 1202507057 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $40.00 | 08/29/2025 | Non-covered Recipient Entity Texas Retina Associates Dallas-Main | A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema | No dispute reported | 06/30/2026 | 1220776243 |
| Principal investigator 1 | ABBVIE INC. | $5,883.94 | 08/27/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy | No dispute reported | 06/30/2026 | 1202506181 |
| Principal investigator 1 | Genentech, Inc. | $8,074.00 | 08/22/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A Phase 1 SAD MD in Diabetic Macular Edema | No dispute reported | 06/30/2026 | 1211663676 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,305.03 | 08/06/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184223740 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,305.03 | 08/06/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184223742 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,305.03 | 08/06/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184223744 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,305.03 | 08/06/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184223746 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,305.03 | 08/06/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184223748 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,305.03 | 08/06/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184223750 |
| Principal investigator 1 | Genentech, Inc. | $2,300.00 | 08/01/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A Phase 1 SAD MD in Diabetic Macular Edema | No dispute reported | 06/30/2026 | 1211663681 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $40.00 | 07/31/2025 | Non-covered Recipient Entity Texas Retina Associates Dallas-Main | A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema | No dispute reported | 06/30/2026 | 1220776241 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $3,407.50 | 07/31/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184114857 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $1,684.00 | 07/16/2025 | Non-covered Recipient Entity Texas Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250364173 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $1,495.00 | 07/16/2025 | Non-covered Recipient Entity Texas Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250364175 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,305.03 | 07/16/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184216412 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,897.31 | 07/16/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184216414 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,897.31 | 07/16/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184216416 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,897.31 | 07/16/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184216418 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,897.31 | 07/16/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184216420 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,897.31 | 07/16/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184216422 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $40,249.95 | 07/11/2025 | Non-covered Recipient Entity Texas Retina Associates | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226088175 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,115.00 | 07/04/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175403750 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $8,995.00 | 07/01/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1B: Randomized PD Pilot; Part 2: Masked, Randomized, Active-comparator-controlled | No dispute reported | 06/30/2026 | 1211663687 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,500.00 | 07/01/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1B: Randomized PD Pilot; Part 2: Masked, Randomized, Active-comparator-controlled | No dispute reported | 06/30/2026 | 1211663692 |
| Recipient | Ocular Therapeutix, Inc. | $10,879.35 | 06/30/2025 | Covered Recipient Physician | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250229176 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,305.03 | 06/30/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184212185 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,305.03 | 06/30/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184212187 |
| Principal investigator 1 | Genentech, Inc. | $15,850.00 | 06/25/2025 | Non-covered Recipient Entity Texas Retina Associates | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211663604 |
| Principal investigator 1 | Genentech, Inc. | $5,002.00 | 06/25/2025 | Non-covered Recipient Entity Texas Retina Associates | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | No dispute reported | 06/30/2026 | 1211663614 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.92 | 06/24/2025 | Non-covered Recipient Entity Texas Retina Associates Dallas-Main | A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema | No dispute reported | 06/30/2026 | 1220776229 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $199.80 | 06/24/2025 | Non-covered Recipient Entity Texas Retina Associates Dallas-Main | A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema | No dispute reported | 06/30/2026 | 1220776231 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 06/24/2025 | Non-covered Recipient Entity Texas Retina Associates Dallas-Main | A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema | No dispute reported | 06/30/2026 | 1220776233 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.70 | 06/24/2025 | Non-covered Recipient Entity Texas Retina Associates Dallas-Main | A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema | No dispute reported | 06/30/2026 | 1220776235 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,110.00 | 06/20/2025 | Non-covered Recipient Entity Texas Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250364191 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $1,223.00 | 06/20/2025 | Non-covered Recipient Entity Texas Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250364193 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,700.00 | 06/04/2025 | Non-covered Recipient Entity Texas Retina Associates | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226088149 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,305.03 | 06/02/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184200913 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,305.03 | 06/02/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184200915 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,305.03 | 06/02/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184200917 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,305.03 | 06/02/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184200919 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,305.03 | 06/02/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184200921 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,897.31 | 06/02/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184201289 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,000.00 | 05/28/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184199663 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,110.00 | 05/16/2025 | Non-covered Recipient Entity Texas Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250364195 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $1,684.00 | 05/16/2025 | Non-covered Recipient Entity Texas Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250364197 |
| Principal investigator 1 | ANI Pharmaceuticals, Inc. | $23,843.75 | 05/15/2025 | Non-covered Recipient Entity Texas Retina Associates 47 | New Day Study | No dispute reported | 06/30/2026 | 1248567393 |
| Principal investigator 1 | ANI Pharmaceuticals, Inc. | $3,271.13 | 05/15/2025 | Non-covered Recipient Entity Texas Retina Associates 47 | New Day Study | No dispute reported | 06/30/2026 | 1248567405 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $7,100.00 | 05/14/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250240103 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $38,744.31 | 05/02/2025 | Non-covered Recipient Entity RETINA FOUNDATION OF THE SOUTHWEST | ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study | No dispute reported | 06/30/2026 | 1190310460 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $25.00 | 04/30/2025 | Non-covered Recipient Entity Texas Retina Associates Dallas-Main | A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema | No dispute reported | 06/30/2026 | 1220776237 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $95.01 | 04/30/2025 | Non-covered Recipient Entity Texas Retina Associates Dallas-Main | A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema | No dispute reported | 06/30/2026 | 1220776239 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,305.03 | 04/23/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184188591 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,305.03 | 04/23/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184188593 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,305.03 | 04/23/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184188595 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,305.03 | 04/23/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184188597 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,416.66 | 04/23/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184188599 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,305.03 | 04/23/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184188601 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,416.66 | 04/23/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184188603 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,305.03 | 04/23/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184188605 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,305.03 | 04/23/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184188607 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $11,857.95 | 04/23/2025 | Non-covered Recipient Entity Texas Retina Associates | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226088136 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $1,223.00 | 04/16/2025 | Non-covered Recipient Entity Texas Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250364189 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $448.80 | 04/16/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184114855 |
| Principal investigator 1 | Genentech, Inc. | $13,144.00 | 04/11/2025 | Non-covered Recipient Entity Texas Retina Associates | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | No dispute reported | 06/30/2026 | 1211663619 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,472.00 | 03/31/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175403743 |
| Principal investigator 1 | Genentech, Inc. | $19,630.00 | 03/26/2025 | Non-covered Recipient Entity Texas Retina Associates | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211663623 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,752.50 | 03/26/2025 | Non-covered Recipient Entity Texas Retina Associates | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226088317 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $1,684.00 | 03/14/2025 | Non-covered Recipient Entity Texas Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250364185 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,237.00 | 03/14/2025 | Non-covered Recipient Entity Texas Retina Associates | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226088076 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,416.66 | 03/12/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172536 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,416.66 | 03/12/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172538 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,416.66 | 03/12/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172540 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,416.66 | 03/12/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172572 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,115.00 | 03/03/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175403739 |
| Principal investigator 1 | Janssen Research & Development, LLC | $629.00 | 03/03/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies | No dispute reported | 06/30/2026 | 1175403757 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $1,495.00 | 02/19/2025 | Non-covered Recipient Entity Texas Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250364177 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $1,495.00 | 02/19/2025 | Non-covered Recipient Entity Texas Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250364179 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $1,495.00 | 02/19/2025 | Non-covered Recipient Entity Texas Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250364181 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $1,495.00 | 02/19/2025 | Non-covered Recipient Entity Texas Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250364183 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,931.00 | 02/03/2025 | Non-covered Recipient Entity TEXAS RETINA ASSOCIATES | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175403733 |
| Principal investigator 1 | ANI Pharmaceuticals, Inc. | $500.00 | 01/30/2025 | Non-covered Recipient Entity Texas Retina Associates 47 | New Day Study | No dispute reported | 06/30/2026 | 1248567627 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $1,495.00 | 01/24/2025 | Non-covered Recipient Entity Texas Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250364187 |